Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein
Status:
Completed
Trial end date:
2016-04-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the dosages of recombinant human serum
albumin/granulocyte colony-stimulating factor fusion protein by injection for preventing
neutrophilic granulocytopenia among chemotherapy patients.
Conduct Pharmacokinetics (PK) study on recombinant human serum albumin/granulocyte
colony-stimulating factor fusion protein with recombinant human granulocyte
colony-stimulating factor injection as a control.